PharmaPoint: Multiple Myeloma Global Drug Forecast and Market Analysis to 2023
Summary
The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.
Highlights
Key Questions Answered
The multiple myeloma market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of multiple myeloma market?
The late-stage multiple myeloma pipeline has therapies targeting different multiple myeloma populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
The current multiple myeloma market is dominated by Velcade and Revlimid. How will the advent of new mAbs change the drug treatment landscape for multiple myeloma? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?
Key Benefits
The main driver of the enormous expansion of the multiple myeloma market will be the launch of mAbs Empliciti and daratumumab.
The second largest driver will be the label extension of currently marketed drugs Kyprolis and Revlimid.
Another driver of the multiple myeloma market will be the ageing population in the 8MM, which will increase the number of multiple myeloma cases.
The increase in therapeutic options overall will lead to increases in treatment rates in the 8MM. Also, as triplet/quadruplet therapies increasingly become the standard of care within the forecast period, this will increase the duration of treatment for each patient as well as the number of treatments each patient receives.
Scope
Overview of multiple myeloma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized multiple myeloma therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the multiple myeloma therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global multiple myeloma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global multiple myeloma therapeutics market from 2013-2023.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table Of Contents
1 Table of Contents 11
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 27
3.2 Staging Systems 30
3.3 Response and Relapse Criteria 31
3.4 Symptoms 33
3.5 Prognosis 34
3.6 Quality of Life 35
4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and Comorbidities 39
4.3 Global Trends 40
4.3.1 Incidence 40
4.3.2 Survival Rates for Multiple Myeloma - 8MM 43
4.4 Forecast Methodology 44
4.4.1 Sources Used 46
4.4.2 Sources Not Used 48
4.4.3 Forecast Assumptions and Methods, Multiple Myeloma Diagnosed Incident Cases 48
4.4.4 Forecast Assumptions and Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases 49
4.4.5 Forecast Assumptions and Methods, Multiple Myeloma Clinical Stages at Diagnosis 50
4.5 Epidemiological Forecast for Multiple Myeloma (2013-2023) 50
4.5.1 Diagnosed Incident Cases of Multiple Myeloma 50
4.5.2 Age-Specific Diagnosed Incident Cases of Multiple Myeloma 52
4.5.3 Sex-Specific Diagnosed Incident Cases of Multiple Myeloma 54
4.5.4 Age-Standardized Diagnosed Incidence of Multiple Myeloma 56
4.5.5 Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis 57
4.5.6 Five-Year Diagnosed Prevalent Cases of Multiple Myeloma 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 60
4.6.3 Strengths of the Analysis 61
5 Disease Management 62
5.1 Treatment Overview 62
5.2 Diagnosis 63
5.3 Clinical Practice 64
5.3.1 Primary Therapy for SCT-Eligible Patients 65
5.3.2 Primary Therapy for Non-SCT Patients 67
5.3.3 Salvage/Relapse Therapy 68
5.3.4 Leading Prescribed Drugs 69
5.4 US 71
5.4.1 Diagnosis 72
5.4.2 Clinical Practice 73
5.5 France 75
5.5.1 Diagnosis 76
5.5.2 Clinical Practice 77
5.6 Germany 77
5.6.1 Diagnosis 79
5.6.2 Clinical Practice 79
5.7 Italy 79
5.7.1 Diagnosis 81
5.7.2 Clinical Practice 81
5.8 Spain 83
5.8.1 Diagnosis 84
5.8.2 Clinical Practice 84
5.9 UK 85
5.9.1 Diagnosis 86
5.9.2 Clinical Practice 87
5.10 Japan 87
5.10.1 Diagnosis 88
5.10.2 Clinical Practice 89
5.11 China (Urban) 90
5.11.1 Diagnosis 91
5.11.2 Clinical Practice 92
6 Competitive Assessment 93
6.1 Overview 93
6.2 Product Profiles - Proteasome Inhibitors 93
6.2.1 Velcade (Bortezomib) 93
6.2.2 Kyprolis (Carfilzomib) 100
6.3 Product Profiles - Immunomodulators 108
6.3.1 Revlimid (Lenalidomide) 108
6.3.2 Pomalyst/Imnovid (Pomalidomide) 115
6.4 Other Therapeutic Classes 120
7 Unmet Need and Opportunity 121
7.1 Overview 121
7.2 Treatment of High-Risk Patients 121
7.2.1 Unmet Need 121
7.2.2 Gap Analysis 122
7.2.3 Opportunity 123
7.3 Treatment of Patients with Smoldering Myeloma 123
7.3.1 Unmet Need 123
7.3.2 Gap Analysis 125
7.3.3 Opportunity 125
7.4 Treatment of Extramedullary Disease 126
7.4.1 Unmet Need 126
7.4.2 Gap Analysis 126
7.4.3 Opportunity 127
8 Pipeline Assessment 128
8.1 Overview 128
8.2 Promising Drugs in Clinical Development 128
8.2.1 Farydak (Panobinostat) 128
8.2.2 Ixazomib 135
8.2.3 Empliciti (Elotuzumab) 140
8.2.4 Daratumumab 146
8.2.5 Aplidin (Plitidepsin) 151
8.3 Promising Drugs in Early-Stage Development 155
8.3.1 Oprozomib (ONX-0912) 155
8.3.2 Filanesib 156
8.3.3 SAR650984 156
8.3.4 Marizomib 158
8.3.5 Evofosfamide 158
8.3.6 LGH447 159
8.3.7 Selinexor (KPT-330) 159
9 Current and Future Players 161
9.1 Overview and Trends in Corporate Strategy 161
9.2 Company Profiles 164
9.2.1 Millennium Pharmaceuticals/Takeda 164
9.2.2 Celgene 166
9.2.3 Onyx Pharmaceuticals/Amgen 168
9.2.4 Novartis 169
9.2.5 AbbVie 171
9.2.6 Bristol-Myers Squibb 172
9.2.7 Janssen 173
10 Market Outlook 175
10.1 Global Markets 175
10.1.1 Forecast 175
10.1.2 Drivers - Global Issues 182
10.1.3 Barriers - Global Issues 183
10.2 US 184
10.2.1 Forecast 184
10.2.2 Key Events 188
10.2.3 Drivers - US 188
10.2.4 Barriers - US 190
10.3 5EU 191
10.3.1 Forecast 191
10.3.2 Key Events 196
10.3.3 Drivers - 5EU 196
10.3.4 Barriers - 5EU 198
10.4 Japan 200
10.4.1 Forecast 200
10.4.2 Key Events 203
10.4.3 Drivers - Japan 203
10.4.4 Barriers - Japan 204
10.5 China (Urban) 205
10.5.1 Forecast 205
10.5.2 Key Events 208
10.5.3 Drivers - China (Urban) 208
10.5.4 Barriers - China (Urban) 209
11 Appendix 211
11.1 Bibliography 211
11.2 Abbreviations 233
11.3 Methodology 237
11.4 Forecasting Methodology 237
11.4.1 Diagnosed Multiple Myeloma Patients 237
11.4.2 Percent of Drug-Treated Patients 238
11.4.3 Drugs Included in Each Therapeutic Class 238
11.4.4 Launch and Patent Expiry Dates 239
11.4.5 General Pricing Assumptions 240
11.4.6 Individual Drug Assumptions 241
11.4.7 Pricing of Pipeline Agents 248
11.4.8 Generic Erosion 255
11.5 Primary Research - KOLs Interviewed for this Report 256
11.6 Primary Research - High-Prescriber Survey 258
11.7 About the Authors 259
11.7.1 Analyst 259
11.7.2 Therapy Director 259
11.7.3 Epidemiologist 259
11.7.4 Global Head of Healthcare 260
11.8 About GlobalData 261
11.9 Disclaimer 261
List Of Tables
1.1 List of Tables
Table 1: Definition of the Classes of Myeloma 29
Table 2: Staging Systems for Multiple Myeloma 31
Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response 32
Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression 32
Table 5: Symptoms of Multiple Myeloma 33
Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma 34
Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression 35
Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma 35
Table 9: Multiple Myeloma Clinical Stages at Diagnosis, Using the ISS Criteria 39
Table 10: Risk Factors and Comorbidities for Multiple Myeloma 40
Table 11: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the US, Ages ?40 Years, 1993-2007 41
Table 12: Trends in the Age-Adjusted Incidence of Multiple Myeloma in the 5EU, Ages ?40 Years, 1993-2007 42
Table 13: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Japan, Ages ?40 Years, 1993-2007 42
Table 14: Trends in the Age-Adjusted Incidence of Multiple Myeloma in Urban China, Ages ?40 Years, 1993-2007 43
Table 15: Trends in the Five-Year Relative Survival (%) of Multiple Myeloma in the 8MM, Both Sexes, 1993-2009 44
Table 16: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Incident Cases 45
Table 17: 8MM, Sources of Epidemiological Data Used for the Forecast for Multiple Myeloma Diagnosed Five-Year Prevalent Cases 45
Table 18: 8MM, Sources of Epidemiological Data Used for the Segmentation of Multiple Myeloma Incident Cases by Clinical Stage at Diagnosis 46
Table 19: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ?40 Years, N, 2013-2023 51
Table 20: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N (Row %), 2013 53
Table 21: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ?40 Years, N (Row %), 2013 55
Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ?40 Years, N, 2013-2023 59
Table 23: Treatment Guidelines for Multiple Myeloma 63
Table 24: Definition of the Classes of Myeloma 64
Table 25: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014 69
Table 26: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013 70
Table 27: Country Profile - US 72
Table 28: Country Profile - France 75
Table 29: Country Profile - Germany 78
Table 30: Country Profile - Italy 80
Table 31: Country Profile - Spain 83
Table 32: Country Profile - UK 86
Table 33: Country Profile - Japan 88
Table 34: Country Profile - China (Urban) 91
Table 35: Product Profile - Velcade 94
Table 36: Results from the Pivotal Phase III APEX Trial for Velcade 96
Table 37: Results from the Pivotal Phase III VISTA Trial for Velcade 97
Table 38 Results from the Subcutaneous versus Intravenous Velcade Phase III trial 97
Table 39: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials 98
Table 40: Velcade SWOT Analysis, 2015 99
Table 41: Global Sales Forecast ($m) for Velcade, 2013-2023 99
Table 42: Product Profile - Kyprolis 101
Table 43 Summary of Phase III Pivotal Trial Results for Kyprolis 104
Table 44: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis 105
Table 45 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis 106
Table 46: Kyprolis SWOT Analysis, 2015 107
Table 47: Global Sales Forecasts ($m) for Kyprolis, 2013-2023 108
Table 48: Product Profile - Revlimid 109
Table 49 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients 111
Table 50 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients 112
Table 51: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid 113
Table 52: Revlimid SWOT Analysis, 2015 114
Table 53: Global Sales Forecast ($m) for Revlimid, 2013-2023 114
Table 54: Product Profile - Pomalyst 115
Table 55: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst 117
Table 56: Summary of Phase III Trial Data for Pomalyst 118
Table 57: Pomalyst SWOT Analysis, 2015 119
Table 58: Global Sales Forecasts ($m) for Pomalyst, 2013-2023 119
Table 59: Summary of Other Therapeutic Classes, 2015 120
Table 60: Pipeline Product Profile - Farydak 129
Table 61: Summary of the Phase III PANORAMA 1 Trial of Farydak 132
Table 62: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Recived at Least Two Prior Lines of Therapy (Including Velcade and an IMiD) 132
Table 63: Summary of the Phase II PANORAMA 2 Trial of Farydak 133
Table 64: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak 133
Table 65: Farydak SWOT Analysis, 2015 135
Table 66: Global Sales Forecast ($m) for Farydak, 2013-2023 135
Table 67: Pipeline Product Profile - Ixazomib 136
Table 68: Response Results from the Phase II Study of Ixazomib 138
Table 69: Ixazomib SWOT Analysis, 2015 139
Table 70: Global Sales Forecast ($m) for Ixazomib, 2013-2023 140
Table 71: Pipeline Product Profile - Empliciti 141
Table 72: Summary of the Phase III ELOQUENT 2 trial of Empliciti 143
Table 73: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone 144
Table 74: Empliciti SWOT Analysis, 2015 145
Table 75: Global Sales Forecast ($m) for Empliciti, 2013-2023 145
Table 76: Pipeline Product Profile - Daratumumab 146
Table 77: Response Results from the Phase II Study of Daratumumab 148
Table 78: Daratumumab SWOT Analysis, 2015 150
Table 79: Global Sales Forecast ($m) for Ddaratumumab, 2013-2023 150
Table 80: Pipeline Product Profile - Aplidin 151
Table 81: Summary of Phase II Clinical Trial Results for Aplidin 153
Table 82: Summary of Grade 3 and 4 Adverse Events of Aplidin 153
Table 83: Aplidin SWOT Analysis, 2015 154
Table 84: Global Sales Forecast ($m) for Aplidin, 2013-2023 154
Table 85: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib 156
Table 86: Summary of the Phase I Efficacy Results of SAR650984 157
Table 87: Summary of the Phase I Efficacy Results of Evofosfamide 159
Table 88: Key Companies in the Multiple Myeloma Market Across the 8MM, 2013-2023 162
Table 89: Millennium Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 166
Table 90: Celgene’s Multiple Myeloma Therapy Portfolio Assessment, 2015 168
Table 91: Onyx Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 169
Table 92: Novartis’ Multiple Myeloma Therapy Portfolio Assessment, 2015 171
Table 93: AbbVie’s Multiple Myeloma Therapy Portfolio Assessment, 2015 172
Table 94: BMS’ Multiple Myeloma Therapy Portfolio Assessment, 2015 173
Table 95: Janssen’s Multiple Myeloma Therapy Portfolio Assessment, 2015 174
Table 96: Annual Global Sales ($m) for Multiple Myeloma by Region, 2013-2023 176
Table 97: Annual Global Sales ($m) for Multiple Myeloma by Drug, 2013-2023 179
Table 98: Global Multiple Multiple Myeloma - Drivers, 2013-2023 182
Table 99: Global Multiple Multiple Myeloma - Barriers, 2013-2023 183
Table 100: US Sales Forecast, Multiple Myeloma, 2013-2023 ($m) 185
Table 101: Key Events Impacting Sales for Multiple Myeloma in the US, 2013-2023 188
Table 102: US Multiple Myeloma - Drivers, 2013-2023 188
Table 103: US Multiple Myeloma - Barriers, 2013-2023 190
Table 104: 5EU Sales Forecast, Multiple Myeloma, 2013-2023 ($m) 192
Table 105: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2013-2023 196
Table 106: 5EU Multiple Myeloma - Drivers and Barriers, 2013-2023 196
Table 107: 5EU Multiple Myeloma - Barriers, 2013-2023 198
Table 108: Japan Sales Forecasts, Multiple Myeloma, 2013-2023 ($m) 201
Table 109: Key Events Impacting Sales for Multiple Myeloma in Japan, 2013-2023 203
Table 110: Japanese Multiple Myeloma - Drivers, 2013-2023 203
Table 111: Japanese Multiple Myeloma - Barriers, 2013-2023 204
Table 112: China (Urban) Sales Forecast, Multiple Myeloma, 2013-2023 ($m) 206
Table 113: Key Events Impacting Sales for Multiple Myeloma in China 2013-2023 208
Table 114: Chinese (Urban) Multiple Myeloma - Drivers, 2013-2023 208
Table 115: Chinese (Urban) Multiple Myeloma - Barriers, 2013-2023 209
Table 116: Multiple Myeloma Diagnosed Incidence, 2013-2023 238
Table 117: Multiple Myeloma Drugs and Pipeline agents, Launch Dates 239
Table 118: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries 240
Table 119: Average Cost of Therapy for Velcade 242
Table 120: Average Duration of Treatment (Weeks) for Velcade 242
Table 121: Average Cost of Therapy for Kyprolis ($) 244
Table 122: Average Duration of Treatment (Weeks) for Kyprolis 244
Table 123: Average Cost of Therapy for Revlimid ($) 245
Table 124: Average Duration of Treatment (Weeks) for Revlimid 246
Table 125: Average Cost of Therapy for Pomalyst/Imnovid ($) 247
Table 126 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid 247
Table 127: Average Cost of Therapy for Farydak ($) 248
Table 128: Duration of Treatment (Weeks) for Farydak 249
Table 129: Average Cost of Therapy for Ixazomib ($) 250
Table 130: Duration of Treatment (Weeks) for Ixazomib 250
Table 131: Average Cost of Therapy for Empliciti ($) 251
Table 132: Duration of Treatment (Weeks) for Empliciti 252
Table 133: Average Cost of Therapy for Daratumumab ($) 253
Table 134: Duration of Treatment (Weeks) for Daratumumab 254
Table 135: Average Cost of Therapy for Daratumumab ($) 255
Table 136: Duration of Treatment (Weeks) for Daratumumab 255
Table 137: Numbers of Prescribers Surveyed in Each Country 258
List Of Figures
1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, Ages ?40 Years, N, 2013-2023 52
Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of Multiple Myeloma, Both Sexes, N, 2013 54
Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of Multiple Myeloma, Ages ?40 Years, N, 2013 56
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of Multiple Myeloma (Cases per 100,000 Population), Ages ?40 Years, by Sex, 2013 57
Figure 5: 8MM, Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis, Ages ?40 Years, N, 2013 58
Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Multiple Myeloma, Both Sexes, Ages ?40 Years, N, 2013-2023 59
Figure 7: SCT-Eligible Typical Patient Journey 65
Figure 8: Non-SCT-Eligible Typical Patient Journey 67
Figure 9: Velcade’s Phase III Development in Multiple Myeloma 95
Figure 10: Kyprolis’s Phase III Development in Multiple Myeloma 102
Figure 11: Revlimid’s Phase III Development in Multiple Myeloma 109
Figure 12: Pomalyst/Imnovid’s Phase III Development in Multiple Myeloma 116
Figure 13: Farydak’s Development in Multiple Myeloma 131
Figure 14: Dosing Schedule for Farydak 134
Figure 15: Ixazomib’s Development in Multiple Myeloma 137
Figure 16: Empliciti's Development in Multiple Myeloma 141
Figure 17: Daratumumab’s Development in Multiple Myeloma 148
Figure 18: Global Sales ($m) of Branded Products for Multiple Myeloma by Company, 2013 - 2023 163
Figure 19: Company Portfolio Gap Analysis in Multiple Myeloma, 2013-2023 164
Figure 20: Annual Global Sales for Multiple Myeloma by Region, 2013-2023 177
Figure 21: Annual Global Sales for Multiple Myeloma by Region - 2013, 2023 178
Figure 22: Annual Global Sales for Multiple Myeloma by Drug, 2013-2023 180
Figure 23: Global Sales for Multiple Myeloma by Drug, 2013 - 2023 181
Figure 24: Annual US Sales for Multiple Myeloma by Drug, 2013-2023 186
Figure 25: US Sales for Multiple Myeloma by Drug, 2013 and 2023 187
Figure 26: Annual 5EU Sales for Multiple Myeloma by Region, 2013-2023 193
Figure 27: Annual 5EU Sales for Multiple Myeloma by Drug, 2013-2023 194
Figure 28: 5EU Sales for Multiple Myeloma by Drug, 2013 and 2023 195
Figure 29: Annual Japanese Sales for Multiple Myeloma by Drug, 2013-2023 201
Figure 30: Japanese Sales for Multiple Myeloma by Drug, 2013 and 2023 202
Figure 31: Annual Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013-2023 206
Figure 32: Chinese (Urban) Sales for Multiple Myeloma by Drug, 2013 and 2023 207
